CRL
Charles River Laboratories
298.00$
-0.8%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +7.5% | -41.2% | +49.0% | +30.1% | -36.7% | +7.7% | +19.2% | +4.5% | -31.0% | -72.2% | +337.5% | – | |
| – | +2.1% | +6.0% | +0.8% | +2.5% | +15.8% | +17.9% | -0.7% | -28.7% | -8.1% | -14.2% | +0.2% | – | |
| – | -14.4% | -14.3% | -0.9% | +16.5% | -10.8% | -23.8% | +29.8% | +36.5% | -24.2% | +26.9% | -11.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1,563.3% | -225.3% | – | – | -159.3% | – | +767.7% | -146.1% | – | -1,666.4% | – | – | |
| – | +18.8% | +1.0% | -50.1% | -1.9% | +95.3% | -21.5% | -40.5% | +0.8% | +150.0% | -37.1% | -44.4% | – | |
| – | +199.6% | -64.0% | -27.9% | -65.5% | +256.9% | -40.2% | -17.9% | -9.8% | +118.6% | +453.6% | – | – | |
| – | +50.8% | – | – | – | – | – | – | – | – | – | – | – | |
| – | +265.8% | +6,627.3% | -4.7% | +1,030.6% | -99.9% | +284,683.9% | -97.9% | -98.7% | +3.2% | +216,863.5% | -44.5% | – | |
| – | – | – | – | – | -23.5% | – | -171.7% | -23.5% | -65.0% | – | -106.7% | – | |
| – | – | -85.2% | -1,658.1% | -27.4% | -63.4% | +38.8% | +115.4% | -32.7% | -66.0% | – | -147.4% | – | |
| – | – | -54.5% | -392.0% | – | -119.8% | – | -279.6% | – | -72.4% | -363.0% | – | – | |
| – | +2.2% | -64.4% | +203.6% | +38.3% | -60.7% | +34.2% | +50.7% | +5.3% | -67.1% | -125.3% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.